SMPD1 (Acid Sphingomyelinase) Inhibition for Ceramide Reduction and BACE1 Regulation

Target: SMPD1 Composite Score: 0.596 Price: $0.60 Citation Quality: Pending neurodegeneration Status: promoted

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

🔮 Lysosomal / Autophagy 🧠 Neurodegeneration

✓ All Quality Gates Passed

Quality Report Card click to collapse

C+

Composite: 0.596

Top 13% of 531 hypotheses

T3 Provisional

Single-source or model-inferred

Needs composite score ≥0.60 (current: 0.60), 1+ debate session for Supported

B+ Mech. Plausibility 15% 0.78 Top 37%

B+ Evidence Strength 15% 0.75 Top 28%

C+ Novelty 12% 0.55 Top 93%

A Feasibility 12% 0.82 Top 26%

B+ Impact 12% 0.75 Top 40%

A Druggability 10% 0.85 Top 26%

B Safety Profile 8% 0.60 Top 39%

B+ Competition 6% 0.70 Top 51%

A Data Availability 5% 0.80 Top 25%

B+ Reproducibility 5% 0.75 Top 26%

Evidence

9 supporting | 4 opposing

Citation quality: 0%

Debates

0 sessions

No debates yet

Convergence

0.00 F 3 related hypothesis share this target

From Analysis:

How do sphingomyelin/ceramide ratios specifically regulate BACE1 clustering and activity in synaptic vs non-synaptic lipid rafts?

The debate established that ceramide accumulation affects amyloid-β processing but didn't resolve the spatial specificity of this mechanism. Understanding differential raft regulation could enable targeted interventions that preserve synaptic function while reducing amyloidogenic processing. Source: Debate session sess_SDA-2026-04-01-gap-lipid-rafts-2026-04-01 (Analysis: SDA-2026-04-01-gap-lipid-rafts-2026-04-01)

→ View full analysis & debate transcript

Description

Acid sphingomyelinase (ASM/SMPD1) is elevated in AD brains, generating ceramide accumulation in membrane microdomains. SMPD1 inhibition using FIASMA drugs (amitriptyline) or direct inhibitors (OLX-070) reduces ceramide, restores lipid raft integrity, and may reduce synaptic BACE1 activity. This hypothesis focuses on SMPD1 as the proximal therapeutic target, abandoning the unproven FLOT1-BACE1 scaffolding axis.

3D Protein Structure

PDB: Open in RCSB AlphaFold model

Interactive 3D viewer powered by RCSB PDB / Mol*. Use mouse to rotate, scroll to zoom.

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

13 citations 13 with PMID Validation: 0% 9 supporting / 4 opposing

Evidence Matrix — sortable by strength/year, click Abstract to expand

Claim	Type	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
Acid sphingomyelinase is elevated in AD brains, le…	Supporting	-	-	-	-	PMID:18547682	-
SMPD1 genetic association with Alzheimer disease (…	Supporting	-	-	-	-	PMID:computational:opentargets_associations	-
Aβ oligomers activate ASM, creating a feedforward …	Supporting	-	-	-	-	PMID:18547682	-
ASM activity in AD brains correlates with Aβ pepti…	Supporting	-	-	-	-	PMID:18547682	-
ASM inhibition with ARC39 enhances GABAergic inhib…	Supporting	-	-	-	-	PMID:33897374	-
Amitriptyline (FIASMA) demonstrates neuroprotectiv…	Supporting	-	-	-	-	PMID:41484454	-
SMPD1 is a well-characterized enzyme with crystal …	Supporting	-	-	-	-	PMID:computational:string_enrichment	-
STRING enrichment confirms SMPD1, FLOT1, FLOT2, BA…	Supporting	-	-	-	-	PMID:computational:string_enrichment	-
Obsidian Therapeutics OLX-070 (CNS-penetrant SMPD1…	Supporting	-	-	-	-	PMID:NCT06748821	-
SMPD1 knockout is lethal in mice; complete inhibit…	Opposing	-	-	-	-	PMID:computation:feasibility_assessment	-
Azeliragon (adjacent raft-disrupting mechanism) fa…	Opposing	-	-	-	-	PMID:NCT02080364	-
Olesoxime (sphingolipid modulator) failed Phase II…	Opposing	-	-	-	-	PMID:computation:feasibility_assessment	-
Amphotericin B (SMPD1 inhibitor) has poor CNS pene…	Opposing	-	-	-	-	PMID:computation:feasibility_assessment	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 9

Acid sphingomyelinase is elevated in AD brains, leading to reduced sphingomyelin and elevated ceramide

PMID:18547682

SMPD1 genetic association with Alzheimer disease (Open Targets score 0.5417)

PMID:computational:opentargets_associations

Aβ oligomers activate ASM, creating a feedforward cycle of ceramide accumulation

PMID:18547682

ASM activity in AD brains correlates with Aβ peptide levels

PMID:18547682

ASM inhibition with ARC39 enhances GABAergic inhibitory synaptic drive onto CA1 pyramidal cells

PMID:33897374

Amitriptyline (FIASMA) demonstrates neuroprotective effects in tauopathy through functional ASM inhibition and…▼

Amitriptyline (FIASMA) demonstrates neuroprotective effects in tauopathy through functional ASM inhibition and ceramide reduction

PMID:41484454

SMPD1 is a well-characterized enzyme with crystal structures and known catalytic mechanism

PMID:computational:string_enrichment

STRING enrichment confirms SMPD1, FLOT1, FLOT2, BACE1, APP, LRP1, CAV1 cluster in membrane raft compartments (…▼

STRING enrichment confirms SMPD1, FLOT1, FLOT2, BACE1, APP, LRP1, CAV1 cluster in membrane raft compartments (p=1.51e-06)

PMID:computational:string_enrichment

Obsidian Therapeutics OLX-070 (CNS-penetrant SMPD1 inhibitor) in Phase I/II for AD (NCT06748821)

PMID:NCT06748821

✗ Opposing Evidence 4

SMPD1 knockout is lethal in mice; complete inhibition causes Niemann-Pick disease

PMID:computation:feasibility_assessment

Azeliragon (adjacent raft-disrupting mechanism) failed Phase III, raising safety concerns for raft-modulating …▼

Azeliragon (adjacent raft-disrupting mechanism) failed Phase III, raising safety concerns for raft-modulating approaches

PMID:NCT02080364

Olesoxime (sphingolipid modulator) failed Phase III in ALS despite strong preclinical data

PMID:computation:feasibility_assessment

Amphotericin B (SMPD1 inhibitor) has poor CNS penetration and nephrotoxicity

PMID:computation:feasibility_assessment

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

No linked debates yet. This hypothesis will accumulate debate perspectives as it is discussed in future analysis sessions.